Morgan Stanley
RUBY

Morgan Stanley’s Rubius Therapeutics, Inc RUBY Stock Holding History

Morgan Stanley’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-62,273
Closed -$10.9K – 7929
2022
Q4 		$10.9K Sell
62,273
-14,057
-18% -$3.84K ﹤0.01% 6901
2022
Q3 		$33K Sell
76,330
-34,770
-31% -$26.1K ﹤0.01% 6589
2022
Q2 		$94K Sell
111,100
-161,637
-59% -$271K ﹤0.01% 6309
2022
Q1 		$1.5M Buy
272,737
+4,655
+2% +$29.6K ﹤0.01% 4723
2021
Q4 		$2.6M Buy
268,082
+143,359
+115% +$1.99M ﹤0.01% 4364
2021
Q3 		$2.23M Buy
124,723
+1,861
+2% +$40.5K ﹤0.01% 4480
2021
Q2 		$3M Buy
122,862
+84,506
+220% +$2.11M ﹤0.01% 4295
2021
Q1 		$1.02M Sell
38,356
-16,943
-31% -$247K ﹤0.01% 4721
2020
Q4 		$419K Buy
55,299
+30,371
+122% +$180K ﹤0.01% 5186
2020
Q3 		$125K Sell
24,928
-195,267
-89% -$1.03M ﹤0.01% 5332
2020
Q2 		$1.32M Buy
220,195
+158,621
+258% +$936K ﹤0.01% 3947
2020
Q1 		$273K Sell
61,574
-42,687
-41% -$317K ﹤0.01% 4732
2019
Q4 		$991K Sell
104,261
-33,521
-24% -$324K ﹤0.01% 4533
2019
Q3 		$1.08M Buy
137,782
+61,637
+81% +$718K ﹤0.01% 4250
2019
Q2 		$1.2M Sell
76,145
-8,102
-10% -$131K ﹤0.01% 4129
2019
Q1 		$1.52M Buy
84,247
+25,888
+44% +$397K ﹤0.01% 3814
2018
Q4 		$939K Buy
58,359
+1,750
+3% +$31.9K ﹤0.01% 4322
2018
Q3 		$1.36M Buy
+56,609
New +$1.29M ﹤0.01% 4302

Other funds holding RUBY

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return

Morgan Stanley's RUBY Position: Q1 2023 in Review

Morgan Stanley sold out of Rubius Therapeutics, Inc (RUBY) in Q1 2023, closing a stake of 62,273 shares — an estimated $10.9K sold.

Morgan Stanley first reported a position in RUBY in Q3 2018 and held it in 18 quarters. The position peaked at $3M in Q2 2021. 7 funds tracked by Wall St. Rank hold RUBY as of Q1 2023.

  • Morgan Stanley reported no remaining Rubius Therapeutics, Inc position as of Q1 2023 after selling out during the quarter.
  • Morgan Stanley sold 62,273 Rubius Therapeutics, Inc shares in Q1 2023, an estimated $10.9K.
  • Morgan Stanley first reported a position in Rubius Therapeutics, Inc in Q3 2018 and held it in 18 quarters.
  • Morgan Stanley's Rubius Therapeutics, Inc position peaked at $3M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q1 2023.

Based on Morgan Stanley's 13F filing for Q1 2023, filed 15 May 2023.